human uterine sarcoma cell lines mes-sa Search Results


96
ATCC multi drug resistant human uterine sarcoma cells mes sa dx5
Multi Drug Resistant Human Uterine Sarcoma Cells Mes Sa Dx5, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multi drug resistant human uterine sarcoma cells mes sa dx5/product/ATCC
Average 96 stars, based on 1 article reviews
multi drug resistant human uterine sarcoma cells mes sa dx5 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

96
ATCC primary epithelioid tumor
Primary Epithelioid Tumor, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary epithelioid tumor/product/ATCC
Average 96 stars, based on 1 article reviews
primary epithelioid tumor - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology antibodies anti hnf1b
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Antibodies Anti Hnf1b, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies anti hnf1b/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
antibodies anti hnf1b - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

sk ut  (ATCC)
95
ATCC sk ut
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Sk Ut, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sk ut/product/ATCC
Average 95 stars, based on 1 article reviews
sk ut - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

93
Bio-Rad whole gel eluter p glycoprotein
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Whole Gel Eluter P Glycoprotein, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/whole gel eluter p glycoprotein/product/Bio-Rad
Average 93 stars, based on 1 article reviews
whole gel eluter p glycoprotein - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
ATCC uterine sarcoma
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Uterine Sarcoma, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/uterine sarcoma/product/ATCC
Average 94 stars, based on 1 article reviews
uterine sarcoma - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

95
ATCC multidrug resistant derivative
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Multidrug Resistant Derivative, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multidrug resistant derivative/product/ATCC
Average 95 stars, based on 1 article reviews
multidrug resistant derivative - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

94
ATCC uterine sarcoma cells
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Uterine Sarcoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/uterine sarcoma cells/product/ATCC
Average 94 stars, based on 1 article reviews
uterine sarcoma cells - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

90
Takeda mes-sa human uterine sarcoma cells
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Mes Sa Human Uterine Sarcoma Cells, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mes-sa human uterine sarcoma cells/product/Takeda
Average 90 stars, based on 1 article reviews
mes-sa human uterine sarcoma cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

96
ATCC uterine
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Uterine, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/uterine/product/ATCC
Average 96 stars, based on 1 article reviews
uterine - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

90
BioResource International Inc human uterine sarcoma cell lines mes-sa
Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , <t>HNF1B</t> , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.
Human Uterine Sarcoma Cell Lines Mes Sa, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human uterine sarcoma cell lines mes-sa/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
human uterine sarcoma cell lines mes-sa - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

92
ATCC uterine sarcoma cell lines
(A) Messenger RNA expression of TrkB, p75NTR and their ligands was detected by RT-PCR in the <t>uterine</t> <t>sarcoma</t> <t>cell</t> <t>lines,</t> MES-SA and MES-SA/Dx5. As loading controls, the levels of β-actin were also assessed. The negative control lacked template DNA. (B) Messenger RNA expression of TrkB, p75NTR, and their ligands, BDNF and NT4/5, in surgical specimens from human uterine leiomyosarcomas was detected by RT-PCR. As loading controls, β-actin mRNA levels were assessed. (C) Expression levels of TrkB, BDNF and NT4/5 in uterine sarcoma cell lines were quantified by real-time RT-PCR. The expression level of each transcript was standardized using levels of β-actin transcripts in the same samples (n = 4). Columns , mean; bars , SE. *, P <0.05 vs. MES-SA. (D) Immunohistochemical detection of TrkB, NT4/5 and BDNF proteins. Target proteins (red signal) were detected in MES-SA/Dx5 cells (Upper panels). Lower panels depict negative controls. Nuclei (blue) were stained with Hoechest 33342. (Scale bars, 50 µm).
Uterine Sarcoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/uterine sarcoma cell lines/product/ATCC
Average 92 stars, based on 1 article reviews
uterine sarcoma cell lines - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

Image Search Results


Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , HNF1B , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.

Journal: Cells

Article Title: FGF2 Inhibits Early Pancreatic Lineage Specification during Differentiation of Human Embryonic Stem Cells

doi: 10.3390/cells9091927

Figure Lengend Snippet: Pancreatic differentiation in presence of growth factors. ( a ) Gene expression of PDX1 , HLXB9 , HNF1B , HNF6 , SHH, TBX1, SOX9, AFP, and CDX2 measured by RT-qPCR in human embryonic stem cells (hESC)s at d0, d4, and d8 of differentiation treated ± 5 or 50 ng/mL fibroblast growth factor (FGF)2, FGF7, FGF10, or epidermal growth factor (EGF) in stage 2 medium. Values are means ± SEM, n = 4–6. 5/50 = 5 or 50 ng/mL growth factor, C = control medium without growth factors. ( b ) Fluorescence micrographs after pancreatic differentiation illustrating the protein expression of PDX1/HNF1B after a 4-day treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF. Nuclei were counterstained with DAPI. Scale bar = 200 µm and 20 µm for higher magnification of the control. ( c ) Quantification of cell expansion using ± 50 ng/mL growth factor. Data are presented as mean (log2) ± SEM, n = 3. ( d ) Quantification of PDX1-positive cells upon treatment ± 5 or 50 ng/mL FGF2, FGF7, FGF10, and EGF at d8. Percentages are expressed as means ± SEM. *** = p ≤ 0.001, ** = p ≤ 0.01 compared to control, ANOVA plus Dunnett’s post-test.

Article Snippet: The primary antibodies anti-HNF1B (SantaCruz, sc-22840, Santa Cruz, CA, USA) and anti-PDX1 (R&D systems, AF2419, Minneapolis, MN, USA) were used.

Techniques: Gene Expression, Quantitative RT-PCR, Control, Fluorescence, Expressing

Gene expression changes in response to different FGF2 concentrations. ( a ) hESCs were cultured in the presence of 5–50 ng/mL FGF2 during differentiation into PDX1-positive cells and compared to a control condition (=C). Gene expression changes of PDX1 , HNF1B , SHH, and TBX1 are presented as means ± SEM, n = 5–12. *** = p ≤ 0.001, ** = p ≤ 0.01, * = p ≤ 0.05 compared to control, ANOVA plus Dunnett’s post-test. ( b ) Effect of SHH inhibition by 10 µM Gant 58 or 2.5 µM Sant1 in stage 2 medium ± 50 ng/mL FGF2. Gene expression changes of PDX1 and SHH are presented as means ± SEM, n = 4–5. *** = p ≤ 0.001, compared to control, ANOVA plus Dunnett’s post-test.

Journal: Cells

Article Title: FGF2 Inhibits Early Pancreatic Lineage Specification during Differentiation of Human Embryonic Stem Cells

doi: 10.3390/cells9091927

Figure Lengend Snippet: Gene expression changes in response to different FGF2 concentrations. ( a ) hESCs were cultured in the presence of 5–50 ng/mL FGF2 during differentiation into PDX1-positive cells and compared to a control condition (=C). Gene expression changes of PDX1 , HNF1B , SHH, and TBX1 are presented as means ± SEM, n = 5–12. *** = p ≤ 0.001, ** = p ≤ 0.01, * = p ≤ 0.05 compared to control, ANOVA plus Dunnett’s post-test. ( b ) Effect of SHH inhibition by 10 µM Gant 58 or 2.5 µM Sant1 in stage 2 medium ± 50 ng/mL FGF2. Gene expression changes of PDX1 and SHH are presented as means ± SEM, n = 4–5. *** = p ≤ 0.001, compared to control, ANOVA plus Dunnett’s post-test.

Article Snippet: The primary antibodies anti-HNF1B (SantaCruz, sc-22840, Santa Cruz, CA, USA) and anti-PDX1 (R&D systems, AF2419, Minneapolis, MN, USA) were used.

Techniques: Gene Expression, Cell Culture, Control, Inhibition

Inhibition of FGFR1c/3c rescues pancreatic development in presence of FGF2 and FGF7. ( a ) Gene expression changes of PDX1 , HNF1B , SHH , and TBX1 in d8 cells treated ± 10 ng/mL FGF2 (F2) and the FGFR1c/3c small molecule inhibitor PD-173074 (PD) with a concentration of 100 nM (PD). Data are means ± SEM, n = 4–5. *** = p ≤ 0.001, ** = p ≤ 0.01, * p = ≤0.05 ANOVA plus Tukey’s post-test, F2 treatment compared to F2 + PD and PD only. ( b ) Representative immunofluorescence staining of PDX1 in d8 control cells, cells treated with F2 and F2 + PD. Nuclei were counterstained with DAPI. Scale bar = 100 µm. ( c ) Gene expression changes of PDX1 , SOX9 , AFP , and CDX2 in d8 cells treated ± 50 ng/mL FGF7 (F7) and ± PD-173074 with a concentration of 10 or 100 nM (10, 100). Values are means ± SEM, n = 3–6, * = p ≤ 0.05, ANOVA plus Tukey’s post-test. ( d ) Quantification of PDX1-positive cells at d8 upon treatment ± 50 ng/mL FGF7 and ± PD-173074 with a concentration of 10 or 100 nM. Percentages are expressed as means ± SEM. * = p ≤ 0.05, ANOVA plus Tukey’s post-test.

Journal: Cells

Article Title: FGF2 Inhibits Early Pancreatic Lineage Specification during Differentiation of Human Embryonic Stem Cells

doi: 10.3390/cells9091927

Figure Lengend Snippet: Inhibition of FGFR1c/3c rescues pancreatic development in presence of FGF2 and FGF7. ( a ) Gene expression changes of PDX1 , HNF1B , SHH , and TBX1 in d8 cells treated ± 10 ng/mL FGF2 (F2) and the FGFR1c/3c small molecule inhibitor PD-173074 (PD) with a concentration of 100 nM (PD). Data are means ± SEM, n = 4–5. *** = p ≤ 0.001, ** = p ≤ 0.01, * p = ≤0.05 ANOVA plus Tukey’s post-test, F2 treatment compared to F2 + PD and PD only. ( b ) Representative immunofluorescence staining of PDX1 in d8 control cells, cells treated with F2 and F2 + PD. Nuclei were counterstained with DAPI. Scale bar = 100 µm. ( c ) Gene expression changes of PDX1 , SOX9 , AFP , and CDX2 in d8 cells treated ± 50 ng/mL FGF7 (F7) and ± PD-173074 with a concentration of 10 or 100 nM (10, 100). Values are means ± SEM, n = 3–6, * = p ≤ 0.05, ANOVA plus Tukey’s post-test. ( d ) Quantification of PDX1-positive cells at d8 upon treatment ± 50 ng/mL FGF7 and ± PD-173074 with a concentration of 10 or 100 nM. Percentages are expressed as means ± SEM. * = p ≤ 0.05, ANOVA plus Tukey’s post-test.

Article Snippet: The primary antibodies anti-HNF1B (SantaCruz, sc-22840, Santa Cruz, CA, USA) and anti-PDX1 (R&D systems, AF2419, Minneapolis, MN, USA) were used.

Techniques: Inhibition, Gene Expression, Concentration Assay, Immunofluorescence, Staining, Control

(A) Messenger RNA expression of TrkB, p75NTR and their ligands was detected by RT-PCR in the uterine sarcoma cell lines, MES-SA and MES-SA/Dx5. As loading controls, the levels of β-actin were also assessed. The negative control lacked template DNA. (B) Messenger RNA expression of TrkB, p75NTR, and their ligands, BDNF and NT4/5, in surgical specimens from human uterine leiomyosarcomas was detected by RT-PCR. As loading controls, β-actin mRNA levels were assessed. (C) Expression levels of TrkB, BDNF and NT4/5 in uterine sarcoma cell lines were quantified by real-time RT-PCR. The expression level of each transcript was standardized using levels of β-actin transcripts in the same samples (n = 4). Columns , mean; bars , SE. *, P <0.05 vs. MES-SA. (D) Immunohistochemical detection of TrkB, NT4/5 and BDNF proteins. Target proteins (red signal) were detected in MES-SA/Dx5 cells (Upper panels). Lower panels depict negative controls. Nuclei (blue) were stained with Hoechest 33342. (Scale bars, 50 µm).

Journal: PLoS ONE

Article Title: Inhibition of Uterine Sarcoma Cell Growth through Suppression of Endogenous Tyrosine Kinase B Signaling

doi: 10.1371/journal.pone.0041049

Figure Lengend Snippet: (A) Messenger RNA expression of TrkB, p75NTR and their ligands was detected by RT-PCR in the uterine sarcoma cell lines, MES-SA and MES-SA/Dx5. As loading controls, the levels of β-actin were also assessed. The negative control lacked template DNA. (B) Messenger RNA expression of TrkB, p75NTR, and their ligands, BDNF and NT4/5, in surgical specimens from human uterine leiomyosarcomas was detected by RT-PCR. As loading controls, β-actin mRNA levels were assessed. (C) Expression levels of TrkB, BDNF and NT4/5 in uterine sarcoma cell lines were quantified by real-time RT-PCR. The expression level of each transcript was standardized using levels of β-actin transcripts in the same samples (n = 4). Columns , mean; bars , SE. *, P <0.05 vs. MES-SA. (D) Immunohistochemical detection of TrkB, NT4/5 and BDNF proteins. Target proteins (red signal) were detected in MES-SA/Dx5 cells (Upper panels). Lower panels depict negative controls. Nuclei (blue) were stained with Hoechest 33342. (Scale bars, 50 µm).

Article Snippet: The human uterine sarcoma cell lines, MES-SA and MES-SA/Dx5, and human uterine leiomyosarcoma cell line, SKN were purchased from the American Type Culture Collection (Manassas, VA, USA) and the Japan Health Science Foundation (Osaka, Japan), respectively.

Techniques: RNA Expression, Reverse Transcription Polymerase Chain Reaction, Negative Control, Expressing, Quantitative RT-PCR, Immunohistochemical staining, Staining

To determine the effects of endogenous TrkB ligands on cell proliferation (A) and survival (B), uterine sarcoma cells (MES-SA/Dx5 cells) were cultured in medium alone (control, C), or with different doses of the TrkB ectodomain (TrkB EC), the pan-Trk inhibitor, K252a, or its inactive analogue, K252b. Cell proliferation activity was determined using the cell proliferation reagent WST1 after 48 h of culture, and cellular apoptosis was quantified using the caspase-3/7 assay after 8 h of culture (n = 3). Columns , mean; bars , SE. *, P <0.05 vs. control. (C) DNA fragmentation was detected by in situ TUNEL staining. Nucleic acids are stained with propidium iodide (red). Representative images were obtained from MES-SA (upper panels) and MES-SA/Dx5 (lower panels) cells after treatment ± K252a (1 µM) or K252b (1 µM). The number of apoptotic cells (green) was increased in the cells with K252a treatment. (Scale bars, 100 µm).

Journal: PLoS ONE

Article Title: Inhibition of Uterine Sarcoma Cell Growth through Suppression of Endogenous Tyrosine Kinase B Signaling

doi: 10.1371/journal.pone.0041049

Figure Lengend Snippet: To determine the effects of endogenous TrkB ligands on cell proliferation (A) and survival (B), uterine sarcoma cells (MES-SA/Dx5 cells) were cultured in medium alone (control, C), or with different doses of the TrkB ectodomain (TrkB EC), the pan-Trk inhibitor, K252a, or its inactive analogue, K252b. Cell proliferation activity was determined using the cell proliferation reagent WST1 after 48 h of culture, and cellular apoptosis was quantified using the caspase-3/7 assay after 8 h of culture (n = 3). Columns , mean; bars , SE. *, P <0.05 vs. control. (C) DNA fragmentation was detected by in situ TUNEL staining. Nucleic acids are stained with propidium iodide (red). Representative images were obtained from MES-SA (upper panels) and MES-SA/Dx5 (lower panels) cells after treatment ± K252a (1 µM) or K252b (1 µM). The number of apoptotic cells (green) was increased in the cells with K252a treatment. (Scale bars, 100 µm).

Article Snippet: The human uterine sarcoma cell lines, MES-SA and MES-SA/Dx5, and human uterine leiomyosarcoma cell line, SKN were purchased from the American Type Culture Collection (Manassas, VA, USA) and the Japan Health Science Foundation (Osaka, Japan), respectively.

Techniques: Cell Culture, Control, Activity Assay, In Situ, TUNEL Assay, Staining